This Article Full Text (PDF) Other Versions of this Article: CVI.00351-06v1 14/3/331    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Haynes, L. M. Articles by Anderson, L. J. Search for Related Content PubMed PubMed Citation Articles by Haynes, L. M. Articles by Anderson, L. J.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00351-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Recombinant Protein-based Assays for the Detection of Antibodies to SARS-CoV Spike and Nucleocapsid Proteins

National Centers for Immunization and Respiratory Diseases, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Branch, Division of Viral and Rickettsial Diseases, Special Pathogens Branch, Poxvirus Activity, Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE, Atlanta, GA, AlphaVax Inc., Research Triangle Park, NC, Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, MA, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

^* To whom correspondence should be addressed. Email: loh5{at}cdc.gov.

	Abstract

Recombinant SARS nucleocapsid and spike protein-based IgG immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to SARS-CoV in sera collected from patients as late as two years post-symptom onset. These assays will be useful for not only routine SARS-CoV diagnostics, but for epidemiological and antibody kinetic studies.